Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab
about
An update on antibody-based immunotherapies for Clostridium difficile infection[Clostridium difficile infections in geriatric patients].Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling.Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display.Screening of Bifidobacteria and Lactobacilli Able to Antagonize the Cytotoxic Effect of Clostridium difficile upon Intestinal Epithelial HT29 Monolayer.A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection.Nonantimicrobial drug targets for Clostridium difficile infections.Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection.Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?The epidemiology of Clostridium difficile infection in patients with cancer.Management of candidemia in patients with Clostridium difficile infection.Bezlotoxumab: First Global Approval.Translational PK/PD of anti-infective therapeutics.Emerging monoclonal antibodies against Clostridium difficile infection.Clostridium difficile toxins A and B: Receptors, pores, and translocation into cells.Effect of Bifidobacterium upon Clostridium difficile Growth and Toxicity When Co-cultured in Different Prebiotic Substrates.Bezlotoxumab for the prevention of Clostridium difficile recurrence.Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection.Use of a neutralizing antibody helps identify structural features critical for binding of Clostridium difficile toxin TcdA to the host cell surface.Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease.Antibodies to Staphylococcus aureus capsular polysaccharides 5 and 8 perform similarly in vitro but are functionally distinct in vivo.The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium difficile Infection.A small-molecule antivirulence agent for treating Clostridium difficile infection.Clostridium difficile infection: new approaches to prevention, non-antimicrobial treatment, and stewardship.Clostridium difficile infection in the elderly: an update on management.A neutralizing antibody that blocks delivery of the enzymatic cargo of Clostridium difficile toxin TcdB into host cells.Functional defects in Clostridium difficile TcdB toxin uptake identify CSPG4 receptor-binding determinants.The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions.Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection.Bezlotoxumab.Clostridioides difficile Biology: Sporulation, Germination, and Corresponding Therapies for C. difficile Infection.A Small Molecule-Screening Pipeline to Evaluate the Therapeutic Potential of 2-Aminoimidazole Molecules Against Clostridium difficile.
P2860
Q26740788-53E3BE1A-B09D-4B5E-8D11-268CAD43956AQ30244040-F848607A-1CA5-4466-AEE8-0924948A7A5EQ35106011-0D07A0E7-2454-4542-8265-2334B389CD57Q36023082-8A46878E-F04F-4AD6-BFC1-BCDAC06C98C9Q36823908-8CD93C5D-29A8-4904-B84F-BA5561E8C818Q37239550-A3CB08AB-7589-4131-BD6C-D1D6B95F2BBEQ38649348-DADCDCD4-0ADD-407E-AFBC-B7C45F07826DQ38668483-6C90FDF0-6C87-4919-9E7B-CE55FA640ACAQ38686710-8C508C36-C52E-4536-83A8-E66ACCEA4ECBQ38823326-DD1C6C90-57E2-4806-90EF-AD6225199059Q38851595-D7B4BF51-061E-4BEF-85A4-253E022580F8Q39025270-6A913A9A-5987-40CE-B5F2-F16F49D737ECQ39039505-8E2A2CCD-FAB0-4973-B568-A29B3E263560Q39168914-DFF90E09-CF0E-4DE6-9F57-F502D536D4DEQ39330563-0EF58554-D33C-4471-8084-A5D7669F2E68Q39723636-3BC18BF9-72FA-4671-A61B-91981BD7EA53Q40095035-DF0C1768-C280-45F4-BE22-031F0440E3B2Q40125340-585CDB93-3AC4-4EBA-BD5C-335731B36E9EQ40135481-BB6C6067-788D-4D59-A893-EB5A3189960DQ40365743-35868314-33B0-4E39-BB3F-ED51363F841EQ40416064-BDAA3DD4-0F20-40BF-BDC9-364CB28CAB1AQ40499019-EEAC1DB5-4674-47D4-9398-174D84DD772FQ40984710-97BC2D7F-068D-4609-BF0C-A96305787E78Q41990887-6C656591-DA9C-42A3-8AD5-F3B325518087Q47142602-7CCC9A9D-4AB7-412E-BB20-128D21258A79Q47694597-B8C8D9D8-E5F0-4D03-AAC4-C2464C30B5A6Q47903919-9C9DD85D-9D07-4D70-A6B0-F1AD82593654Q48059378-46D79A7D-3AD0-4160-9E4C-6E2164A9C742Q49201152-AE8404BD-92E6-4A65-844A-26EAE22BD72FQ53762105-57C278E5-E60D-4FD3-A47B-AC170C99F28DQ54267984-9C7943D8-B2A7-4CE3-A45C-32C0C01F9E83Q55333418-E542C046-15B1-40B5-90E1-F4D93088646F
P2860
Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Mechanisms of protection again ...... ies actoxumab and bezlotoxumab
@ast
Mechanisms of protection again ...... ies actoxumab and bezlotoxumab
@en
Mechanisms of protection again ...... ies actoxumab and bezlotoxumab
@nl
type
label
Mechanisms of protection again ...... ies actoxumab and bezlotoxumab
@ast
Mechanisms of protection again ...... ies actoxumab and bezlotoxumab
@en
Mechanisms of protection again ...... ies actoxumab and bezlotoxumab
@nl
prefLabel
Mechanisms of protection again ...... ies actoxumab and bezlotoxumab
@ast
Mechanisms of protection again ...... ies actoxumab and bezlotoxumab
@en
Mechanisms of protection again ...... ies actoxumab and bezlotoxumab
@nl
P2093
P2860
P356
P1476
Mechanisms of protection again ...... ies actoxumab and bezlotoxumab
@en
P2093
Alex G Therien
Hanping Feng
Harris G Yfantis
Jamie M Furneisen
Jeremy Ramsey
Lorraine D Hernandez
Nicole M Davis
Therwa Hamza
P2860
P304
P356
10.1128/IAI.02897-14
P407
P577
2014-12-08T00:00:00Z